New study tests if SPECT imaging can forecast prostate cancer treatment success

NCT ID NCT07643935

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will look at whether SPECT scans taken after Lu-PSMA therapy can help predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) are doing. Researchers will measure tumor activity and volume on the scans and compare them to standard PET-based assessments. The goal is to find the best timing for evaluating treatment response, which could help doctors personalize care. The study plans to enroll 280 patients who have already received at least two cycles of Lu-PSMA therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

177Lu-PSMA-617 (a radioactive drug for imaging and treatment)

What this could lead to

If successful, this could help doctors better predict how patients with advanced prostate cancer will respond to Lu-PSMA therapy, potentially guiding treatment decisions.

What could go wrong

This is an observational study, not a test of a new treatment. It may not lead to immediate changes in care, and results might not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma Neoplasms, Second Primary therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••